The platelet activating factor acetyl hydrolase, oxidized low-density lipoprotein, paraoxonase 1 and arylesterase levels in treated and untreated patients with polycystic ovary syndrome.
OBJECTIVE
To evaluate the platelet activating factor acetyl hydrolyze (PAF-AH), oxidized low-density lipoprotein (ox-LDL), paraoxonase 1 (PON1), arylesterase (ARE) levels and the effects of metformin and Diane-35 (ethinyl oestradiol + cyproterone acetate) therapies on these parameters and to determine the PON1 polymorphisms among PCOS patients.


METHODS
Ninety patients with PCOS, age 30, and body mass index-matched healthy controls were included in the study. Patients were divided into three groups: metformin treatment, Diane-35 treatment and no medication groups. The treatment with metformin or Diane-35 was continued for 6 months and all subjects were evaluated with clinical and biochemical parameters 6 months later. One-way Anova test, t test and non-parametric Mann-Whitney U tests were used for statistical analysis.


RESULTS
PAF-AH and ox-LDL levels were statistically significantly higher in untreated PCOS patients than controls, and they were statistically significantly lower in patients treated with metformin or Diane-35 than untreated PCOS patients. In contrast, there were lower PON1 (not statistically significant) and ARE (statistically significant) levels in untreated PCOS patients than the control group and they significantly increased after metformin and Diane-35 treatments. In PCOS patients serum PON1 levels for QQ, QR and RR phenotypes were statistically significantly lower than the control group.


CONCLUSIONS
In patients with PCOS, proatherogenic markers increase. The treatment of PCOS with metformin or Diane-35 had positive effects on lipid profile, increased PON1 level, which is a protector from atherosclerosis and decreased the proatherogenic PAF-AH and ox-LDL levels.
Department of Endocrinology, Regional Education and Research Hospital, Erzurum, Turkey.
Ayse
A
Carlioglu
Ikbal
I
Kaygusuz
Feridun
F
Karakurt
Ilknur Inegol
II
Gumus
Aysel
A
Uysal
Benan
B
Kasapoglu
Ferah
F
Armutcu
Sema
S
Uysal
Esra Aktepe
EA
Keskin
Cemile
C
Koca
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000097:blood* / Q000235:genetics*; D000328:Adult; D000726:Androgen Antagonists / Q000627:therapeutic use; D043303:Aryldialkylphosphatase / Q000097:blood*; D015992:Body Mass Index; D002265:Carboxylic Ester Hydrolases / Q000097:blood*; D016022:Case-Control Studies; D017373:Cyproterone Acetate / Q000627:therapeutic use*; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008077:Lipoproteins, LDL / Q000097:blood*; D008687:Metformin / Q000627:therapeutic use*; D064801:Phospholipase A2 Inhibitors / Q000097:blood*; D010972:Platelet Activating Factor; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D020641:Polymorphism, Single Nucleotide; D016896:Treatment Outcome
D000726:Androgen Antagonists; D004338:Drug Combinations; D007004:Hypoglycemic Agents; D008077:Lipoproteins, LDL; D064801:Phospholipase A2 Inhibitors; D010972:Platelet Activating Factor; C099252:oxidized low density lipoprotein; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; C032640:Cyproterone acetate, ethinyl estradiol drug combination; D008687:Metformin; D002265:Carboxylic Ester Hydrolases; C019734:arylesterase; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; D043303:Aryldialkylphosphatase